Beyond market trends, investors keen on maximizing returns delve into the world of stock picking. The right selections can be instrumental in catapulting your wealth.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
As of close of business last night, NovoCure Ltd’s stock clocked out at $19.69, up 10.12% from its previous closing price of $17.88. In other words, the price has increased by $10.12 from its previous closing price. On the day, 1.08 million shares were traded. NVCR stock price reached its highest trading level at $19.77 during the session, while it also had its lowest trading level at $17.998.
Ratios:
To gain a deeper understanding of NVCR’s stock, we examine its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 1.44 and its Current Ratio is at 1.49. In the meantime, Its Debt-to-Equity ratio is 1.87 whereas as Long-Term Debt/Eq ratio is at 0.33.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for the company, H.C. Wainwright on October 16, 2024, Upgraded its rating to Buy and sets its target price to $30 from $24 previously.
H.C. Wainwright Downgraded its Buy to Neutral on August 28, 2023, whereas the target price for the stock was revised from $85 to $25.
Insider Transactions:
Investing in insider trades can also provide an investor with insight into how management views future stock prices. A recent insider transaction in this stock occurred on Nov 02 ’24 when Paravasthu Mukund sold 44 shares for $16.69 per share. The transaction valued at 734 led to the insider holds 3,459 shares of the business.
Puri Michal Nath sold 810 shares of NVCR for $12,792 on Oct 31 ’24. The Chief Human Resources Officer now owns 110,093 shares after completing the transaction at $15.79 per share. On Nov 01 ’24, another insider, Leonard Frank X, who serves as the EVP, Pres., Novocure Oncology of the company, sold 598 shares for $15.94 each. As a result, the insider received 9,531 and left with 161,236 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, NVCR now has a Market Capitalization of 2130477696 and an Enterprise Value of 1846214272. For the stock, the TTM Price-to-Sale (P/S) ratio is 4.06 while its Price-to-Book (P/B) ratio in mrq is 5.90. Its current Enterprise Value per Revenue stands at 3.196 whereas that against EBITDA is -13.13.
Stock Price History:
Over the past 52 weeks, NVCR has reached a high of $24.74, while it has fallen to a 52-week low of $11.29. The 50-Day Moving Average of the stock is 18.92%, while the 200-Day Moving Average is calculated to be 14.60%.
Shares Statistics:
It appears that NVCR traded 1.04M shares on average per day over the past three months and 754930 shares per day over the past ten days. A total of 107.08M shares are outstanding, with a floating share count of 97.35M. Insiders hold about 10.03% of the company’s shares, while institutions hold 85.89% stake in the company. Shares short for NVCR as of 1731628800 were 5669287 with a Short Ratio of 5.46, compared to 1728950400 on 5775914. Therefore, it implies a Short% of Shares Outstanding of 5669287 and a Short% of Float of 6.260000000000001.
